Detection of subclinical recurrence or second primary cancer using <sup>18</sup>F‐FDG PET/CT in patients treated curatively for head and neck squamous cell carcinoma

Kikuchi, Masahiro; Shinohara, Shogo; Hino, Megumu; Itoh, Kyo; Tona, Risa; Kishimoto, Ippei; Harada, Hiroyuki; Fujiwara, Kenshu; Suehiro, Atsushi; Naito, Yasushi

doi:10.1002/hed.24032

Cited by 6 publications

(5 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several authors suggest performing surveillance imaging (mainly PET-CT) at 1 or 2 time points after the initial post-treatment scan. Suggested regimens are PET-CT exams at 12 months [ 41 ], 12 and 24 months [ 40 ], 9 months [ 33 ], 12 months [ 36 ], 12 months and 18–24 months [ 32 ], 18 months [ 42 ], 8 and 14 months [ 38 ], and 24 months [ 39 ]. Of particular interest is the report of McDermott et al [ 38 ].…”

Section: Resultsmentioning

confidence: 99%

Post-treatment surveillance imaging in head and neck cancer: a systematic review

Van Hoe,

Hermans

2024

Insights Imaging

View full text Add to dashboard Cite

Background In patients treated for head and neck cancer, imaging studies are usually obtained within 3–6 months after treatment for assessment of treatment response. After 6 months, most guidelines advocate clinical follow-up, with imaging reserved for patients with clinically suspect or equivocal findings. However, some guidelines do recommend systematic imaging surveillance, and many clinicians tend to include some type of imaging in their follow-up schemes. Objectives This systematic review focuses on the usefulness of routine (systematic) post-treatment imaging surveillance of head and neck cancer beyond the first 3–6-month baseline imaging study. Methods A systematic literature search was conducted using PubMed and Google Scholar. Additional studies were identified by reviewing reference lists. Only original studies and review papers were considered. Results obtained with systematic post-treatment surveillance imaging were compared to symptom-directed imaging and/or clinical finding-directed imaging. Results Five hundred twenty-one records were identified through the database search, and 44 additional records were identified through other sources. Forty-eight articles were selected for the final review. Analysis of these records showed that almost half of cases of locoregional recurrences and/or metastases were only detected by imaging (40.9%), and the mean time of detection of recurrent or metastatic disease (11.5 months) was well beyond the period of the first post-treatment scan. Most authors reported superior results with PET-CT when compared to other imaging techniques. Conclusion Strong arguments were found in favor of systematic imaging surveillance in locoregional advanced head and neck cancer during at least one and preferably 2 years after treatment. Critical relevance statement Analysis of the selected records showed that almost half of cases of locoregional recurrences and/or metastases were only detected by imaging. This systematic review suggests that imaging may currently be underused in the post-treatment surveillance of patients with head and neck cancer. Key points • This systematic review focuses on the usefulness of long-term systematic imaging surveillance in patients treated for head and neck cancer. • Analysis of 521 articles revealed that systematic imaging allowed the initial detection of locoregional recurrences and/or metastases in more than 40% of patients. • Imaging may currently be underused in the post-treatment surveillance of patients with advanced head and neck cancer. Graphical Abstract

show abstract

Section: Resultsmentioning

confidence: 99%

Post-treatment surveillance imaging in head and neck cancer: a systematic review

Van Hoe,

Hermans

2024

Insights Imaging

View full text Add to dashboard Cite

show abstract

“…9 This was contrasted by another study that concluded that the early use of [ 18 F]FDG PET/CT within 4 months after the completion of definitive treatment of head and neck squamous cell carcinoma (SCC) can detect subclinical disease recurrence and may improve survival. 10 We hypothesized that this discordance may be because of subsite-specific differences with regard to the sensitivity of clinical examination and in sites such as the larynx, in which direct visualization is more difficult, surveillance within 6 months of treatment with [ 18 F]FDG PET/CT will improve cancer-specific survival.…”

Section: F]fludeoxyglucose ([ 18 F]fdg)mentioning

confidence: 99%

“…A recent single‐institution, retrospective study specifically examining human papillomavirus (HPV)–associated squamous cell OPC reported that nearly all clinically detected recurrences were found as a result of symptoms that prompted the patient to an earlier presentation to the clinician, with the authors suggesting a reduction in posttreatment clinical surveillance 9 . This was contrasted by another study that concluded that the early use of [ 18 F]FDG PET/CT within 4 months after the completion of definitive treatment of head and neck squamous cell carcinoma (SCC) can detect subclinical disease recurrence and may improve survival 10 . We hypothesized that this discordance may be because of subsite‐specific differences with regard to the sensitivity of clinical examination and in sites such as the larynx, in which direct visualization is more difficult, surveillance within 6 months of treatment with [ 18 F]FDG PET/CT will improve cancer‐specific survival.…”

Section: Introductionmentioning

confidence: 99%

Comparative effectiveness of posttreatment imaging modalities for Medicare patients with advanced head and neck cancer

Morgan

Eguchi

McDermott

et al. 2020

Cancer

View full text Add to dashboard Cite

Background Persistent controversy exists with regard to how and when patients with head and neck cancer should undergo imaging after definitive therapy. The current study was conducted to evaluate whether the type of imaging modality used in posttreatment imaging impacts cancer‐specific survival for patients with advanced head and neck squamous cell carcinoma. Methods A retrospective study of National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) program–Medicare‐linked data in patients with an advanced stage of the 3 most common head and neck malignancies (oral cavity, oropharynx, and larynx) was conducted. Hazard ratios and 95% CIs for cancer‐specific survival were estimated for patients diagnosed with any of these cancers between 2006 and 2015. Results Significant improvement with regard to cancer‐specific survival was observed among patients with American Joint Committee on Cancer stage III and stage IVA laryngeal cancer who underwent positron emission tomography (PET) and/or computed tomography (CT) imaging during the first 6 months after receipt of definitive treatment (hazard ratio, 0.517; 95% CI, 0.33‐0.811) compared with those who underwent CT. There was a trend toward an improvement in cancer‐specific survival among patients with oral cavity or oropharyngeal malignancies who underwent PET/CT imaging, but it did not reach statistical significance. Conclusions Compared with CT imaging, posttreatment imaging with PET was associated with improved survival in patients with advanced laryngeal carcinoma.

show abstract

“…Zudem kann die Sensitivität deutlich erhöht werden und die Anzahl der falsch positiven Befunde relevant gesenkt werden, wenn die Patienten erst 12 Wochen nach Therapieende untersucht werden [42]. Zwar haben einzelne Studien versucht, die Genauigkeit der PET/CT in der Nachsorge zu untersuchen, problematisch ist hier jedoch, dass in diesen Studien ein Vergleich mit der bisher üblichen Nachsorge im CT nicht erfolgte [43,44]. Eine neue Studie von Kim et al konnte zeigen, dass das PET/CT im Vergleich zum Staging mittels MRT und CT eine höhere Genauigkeit für die Detektion von Rezidiven bietet (AUC in der ROC Analyse: PET/CT: 0,925 gegen CT/MRT: 0,789).…”

Section: Rezidivdiagnostikunclassified

PET/CT versus PET/MRT bei Kopf-Hals-Tumoren

Schaarschmidt

Umutlu

Zarrad

et al. 2020

Der Nuklearmediziner

View full text Add to dashboard Cite

ZusammenfassungDie Einführung der integrierten Positronenemissionstomografie/Magnetresonanztomografie (PET/MRT) bietet in der Bildgebung von Kopf-/Halstumoren neue Möglichkeiten der funktionellen Weichteildarstellung. Insbesondere in der Bildgebung von Plattenepithelkarzinomen des Kopf-/Halsbereichs bietet die PET/MRT deutliche Vorteile in der Primär- und Rezidivdiagnostik. Daher soll im Rahmen dieser Übersichtsarbeit der aktuelle Forschungsstand dargestellt werden und das zukünftige Potenzial dieser Modalität aufgezeigt werden.

show abstract

Detection of subclinical recurrence or second primary cancer using ¹⁸F‐FDG PET/CT in patients treated curatively for head and neck squamous cell carcinoma

Abstract: Earlier detection of subclinical lesions by surveillance PET/CT within 4 months after treatment may improve survival in patients with HNSCC. © 2015 Wiley Periodicals, Inc. Head Neck 38: E511-E518, 2016.

Cited by 6 publications

References 24 publications

Post-treatment surveillance imaging in head and neck cancer: a systematic review

Post-treatment surveillance imaging in head and neck cancer: a systematic review

Comparative effectiveness of posttreatment imaging modalities for Medicare patients with advanced head and neck cancer

PET/CT versus PET/MRT bei Kopf-Hals-Tumoren

Contact Info

Product

Resources

About

Detection of subclinical recurrence or second primary cancer using 18F‐FDG PET/CT in patients treated curatively for head and neck squamous cell carcinoma

Abstract: Earlier detection of subclinical lesions by surveillance PET/CT within 4 months after treatment may improve survival in patients with HNSCC. © 2015 Wiley Periodicals, Inc. Head Neck 38: E511-E518, 2016.

Cited by 6 publications

References 24 publications

Post-treatment surveillance imaging in head and neck cancer: a systematic review

Post-treatment surveillance imaging in head and neck cancer: a systematic review

Comparative effectiveness of posttreatment imaging modalities for Medicare patients with advanced head and neck cancer

PET/CT versus PET/MRT bei Kopf-Hals-Tumoren

Contact Info

Product

Resources

About

Detection of subclinical recurrence or second primary cancer using ¹⁸F‐FDG PET/CT in patients treated curatively for head and neck squamous cell carcinoma